Crossmark

Stop Alzheimer’s before it starts

Crossref DOI link: https://doi.org/10.1038/547153a

Published Online: 2017-07-13

Published Print: 2017-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

McDade, Eric

Bateman, Randall J.
License Information

Text and Data Mining valid from 2017-07-01
More Information

Article History

First Online: 13 July 2017

Competing interests

: R.J.B. receives lab research funding from the Tau SILK Consortium (AbbVie, Biogen and Eli Lilly and Co.), funding for clinical trials from Eli Lilly, Roche, Janssen, Avid Radiopharmaceuticals and research funding from the DIAN Pharma Consortium (Abbvie, Amgen, AstraZeneca, Biogen, Eisai, Eli Lilly, Roche, Janssen, Pfizer and Sanofi). He has received honoraria from Janssen and Pfizer as a speaker, and income from Merck C2N Diagnostics and Pfizer as an Advisory Board member. Washington University, R.J.B. and David Holzman (chair of the Department of Neurology) have equity ownership interest in C2N Diagnostics and receive royalty income based on technology (stable isotope labelling kinetics and blood plasma assay) licensed by Washington University to C2N Diagnostics.